drugset
drugset / Trial / NCT01170338

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

NCT01170338 ↗

Phase 4 Unknown 100 enrolled Newark Beth Israel Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Timeline

Start
2008-01
Primary completion
2011-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 100 mg Oral

Indications

acute coronary syndrome